Althaea rosea Cavanil and Plantago major L. suppress neoplastic cell transformation through the inhibition of epidermal growth factor receptor kinase

Choi,Eun-Sun; Cho,Sung-Dae; Shin,Ji-Ae; Kwon,Ki  Han; Cho,Nam-Pyo; Shim,Jung-Hyun

doi:10.3892/mmr.2012.977

Althaea rosea Cavanil and Plantago major L. suppress neoplastic cell transformation through the inhibition of epidermal growth factor receptor kinase

Authors:
- Eun-Sun Choi
- Sung-Dae Cho
- Ji-Ae Shin
- Ki Han Kwon
- Nam-Pyo Cho
- Jung-Hyun Shim
View Affiliations

Affiliations: Department of Oral Pathology, School of Dentistry and Institute of Oral Bioscience, Brain Korea 21 project, Chonbuk National University, Jeonju 561-756, Republic of Korea , Department of Food Science and Nutrition, College of Health, Welfare and Education, Gwangju University, Gwangju 503-703, Republic of Korea, Department of Biochemistry, College of Medicine, Soonchunhyang University, Cheonan 331-090, Republic of Korea
Published online on: July 4, 2012 https://doi.org/10.3892/mmr.2012.977
Pages: 843-847

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

For thousands of years in Asia, Althaea rosea Cavanil (ARC) and Plantago major L. (PML) have been used as powerful non-toxic therapeutic agents that inhibit inflammation. However, the anticancer mechanisms and molecular targets of ARC and PML are poorly understood, particularly in epidermal growth factor (EGF)-induced neoplastic cell transformation. The aim of this study was to evaluate the chemopreventive effects and mechanisms of the methanol extracts from ARC (MARC) and PML (MPML) in EGF-induced neoplastic cell transformation of JB6 P+ mouse epidermal cells using an MTS assay, anchorage-independent cell transformation assay and western blotting. Our results showed that MARC and MPML significantly suppressed neoplastic cell transformation by inhibiting the kinase activity of the EGF receptor (EGFR). The activation of EGFR by EGF was suppressed by MARC and MPML treatment in EGFR+/+ cells, but not in EGFR-/- cells. In addition, MARC and MPML inhibited EGF-induced cell proliferation in EGFR-expressing murine embryonic fibroblasts (EGFR+/+). These results strongly indicate that EGFR targeting by MARC and MPML may be a good strategy for chemopreventive or chemotherapeutic applications.

View Figures

View References

1	Wang H, Zhou M, Shi B, et al: Identification of an exon 4-deletion variant of epidermal growth factor receptor with increased metastasis-promoting capacity. Neoplasia. 13:461–471. 2011.PubMed/NCBI
2	Xue C, Wyckoff J, Liang F, et al: Epidermal growth factor receptor overexpression results in increased tumor cell motility in vivo coordinately with enhanced intravasation and metastasis. Cancer Res. 66:192–197. 2006. View Article : Google Scholar : PubMed/NCBI
3	Pandiella A, Lehvaslaiho H, Magni M, Alitalo K and Meldolesi J: Activation of an EGFR/neu chimeric receptor: early intracellular signals and cell proliferation responses. Oncogene. 4:1299–1305. 1989.PubMed/NCBI
4	Liang K, Ang KK, Milas L, Hunter N and Fan Z: The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys. 57:246–254. 2003. View Article : Google Scholar : PubMed/NCBI
5	Ho R, Minturn JE, Hishiki T, et al: Proliferation of human neuroblastomas mediated by the epidermal growth factor receptor. Cancer Res. 65:9868–9875. 2005. View Article : Google Scholar : PubMed/NCBI
6	Modjtahedi H and Essapen S: Epidermal growth factor receptor inhibitors in cancer treatment: advances, challenges and opportunities. Anticancer Drugs. 20:851–855. 2009. View Article : Google Scholar : PubMed/NCBI
7	Engelman JA and Cantley LC: A sweet new role for EGFR in cancer. Cancer Cell. 13:375–376. 2008. View Article : Google Scholar : PubMed/NCBI
8	Chaffanet M, Chauvin C, Laine M, et al: EGF receptor amplification and expression in human brain tumours. Eur J Cancer. 28:11–17. 1992. View Article : Google Scholar
9	Nishikawa R, Ji XD, Harmon RC, et al: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc Natl Acad Sci USA. 91:7727–7731. 1994. View Article : Google Scholar : PubMed/NCBI
10	Tang P, Steck PA and Yung WK: The autocrine loop of TGF-alpha/EGFR and brain tumors. J Neurooncol. 35:303–314. 1997. View Article : Google Scholar : PubMed/NCBI
11	Hwang MK, Bode AM, Byun S, et al: Cocarcinogenic effect of capsaicin involves activation of EGFR signaling but not TRPV1. Cancer Res. 70:6859–6869. 2010. View Article : Google Scholar : PubMed/NCBI
12	Newman DJ, Cragg GM and Snader KM: Natural products as sources of new drugs over the period 1981–2002. J Nat Prod. 66:1022–1037. 2003.PubMed/NCBI
13	Graham JG, Quinn ML, Fabricant DS and Farnsworth NR: Plants used against cancer - an extension of the work of Jonathan Hartwell. J Ethnopharmacol. 73:347–377. 2000. View Article : Google Scholar : PubMed/NCBI
14	Samuelsen AB: The traditional uses, chemical constituents and biological activities of Plantago major L. A review. J Ethnopharmacol. 71:1–21. 2000. View Article : Google Scholar : PubMed/NCBI
15	Galvez M, Martin-Cordero C, Lopez-Lazaro M, Cortes F and Ayuso MJ: Cytotoxic effect of Plantago spp. on cancer cell lines. J Ethnopharmacol. 88:125–130. 2003.
16	Papiez MA: The influence of hollyhock extract administration on testicular function in rats. J Mol Histol. 35:733–740. 2004. View Article : Google Scholar : PubMed/NCBI
17	Kang NJ, Lee KW, Rogozin EA, et al: Equol, a metabolite of the soybean isoflavone daidzein, inhibits neoplastic cell transformation by targeting the MEK/ERK/p90RSK/activator protein-1 pathway. J Biol Chem. 282:32856–32866. 2007. View Article : Google Scholar : PubMed/NCBI
18	Ehmann LM, Heinemann V and Wollenberg A: New tyrosine kinase and EGFR inhibitors in cancer therapy: Cardiac and skin toxicity as relevant side effects. Part B: skin. Internist (Berl). 52:1359–1364. 2011.(In German).
19	Cheung CW, Gibbons N, Johnson DW and Nicol DL: Silibinin - a promising new treatment for cancer. Anticancer Agents Med Chem. 10:186–195. 2010. View Article : Google Scholar : PubMed/NCBI
20	Fahey JW, Haristoy X, Dolan PM, et al: Sulforaphane inhibits extracellular, intracellular, and antibiotic-resistant strains of Helicobacter pylori and prevents benzo[a]pyrene-induced stomach tumors. Proc Natl Acad Sci USA. 99:7610–7615. 2002. View Article : Google Scholar : PubMed/NCBI
21	Yanaka A, Fahey JW, Fukumoto A, et al: Dietary sulforaphane-rich broccoli sprouts reduce colonization and attenuate gastritis in Helicobacter pylori-infected mice and humans. Cancer Prev Res (Phila). 2:353–360. 2009. View Article : Google Scholar : PubMed/NCBI
22	Butler MS: The role of natural product chemistry in drug discovery. J Nat Prod. 67:2141–2153. 2004. View Article : Google Scholar : PubMed/NCBI
23	Koehn FE and Carter GT: The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 4:206–220. 2005. View Article : Google Scholar : PubMed/NCBI
24	Shokrzadeh M, Azadbakht M, Ahangar N, Hashemi A and Saeedi Saravi SS: Cytotoxicity of hydro-alcoholic extracts of Cucurbitapepo and Solanum nigrum on HepG2 and CT26 cancer cell lines. Pharmacogn Mag. 6:176–179. 2010. View Article : Google Scholar : PubMed/NCBI
25	Etkin NL: A Hausa herbal pharmacopoeia: biomedical evaluation of commonly used plant medicines. J Ethnopharmacol. 4:75–98. 1981. View Article : Google Scholar : PubMed/NCBI
26	Misumi N, Hiraike M, Nawata F, et al: [Protective effects of d-chlorpheniramine maleate pre-treatment against acute side effects of Irinotecan(CPT- 11)]. Gan To Kagaku Ryoho. 38:1149–1153. 2011.(In Japanese).
27	Sun X, Zhang J, Gupta R, Macgibbon AK, Kuhn-Sherlock B and Krissansen GW: Dairy milk fat augments paclitaxel therapy to suppress tumour metastasis in mice, and protects against the side-effects of chemotherapy. Clin Exp Metastasis. 28:675–688. 2011. View Article : Google Scholar : PubMed/NCBI
28	Wang DF, Shang JY and Yu QH: Analgesic and anti-inflammatory effects of the flower of Althaea rosea (L.) Cav. Zhongguo Zhong Yao Za Zhi. 14(46–48): 641989.(In Chinese).
29	Furuse J: Growth factors as therapeutic targets in HCC. Crit Rev Oncol Hematol. 67:8–15. 2008. View Article : Google Scholar : PubMed/NCBI
30	Khalil MY, Grandis JR and Shin DM: Targeting epidermal growth factor receptor: novel therapeutics in the management of cancer. Expert Rev Anticancer Ther. 3:367–380. 2003. View Article : Google Scholar : PubMed/NCBI
31	Mimeault M, Pommery N and Henichart JP: New advances on prostate carcinogenesis and therapies: involvement of EGF-EGFR transduction system. Growth Factors. 21:1–14. 2003. View Article : Google Scholar : PubMed/NCBI
32	Amstad PA, Liu H, Ichimiya M, Berezesky IK and Trump BF: Manganese superoxide dismutase expression inhibits soft agar growth in JB6 clone41 mouse epidermal cells. Carcinogenesis. 18:479–484. 1997. View Article : Google Scholar : PubMed/NCBI
33	Kang NJ, Lee KW, Kwon JY, et al: Delphinidin attenuates neoplastic transformation in JB6 Cl41 mouse epidermal cells by blocking Raf/mitogen-activated protein kinase kinase/extracellular signal-regulated kinase signaling. Cancer Prev Res (Phila). 1:522–531. 2008. View Article : Google Scholar
34	Dong Z and Bode AM: Proceedings - targeting carcinogenesis: transduction, transcription, translation. Mol Carcinog. 45:353–354. 2006. View Article : Google Scholar : PubMed/NCBI
35	Nguyen-Ba G and Vasseur P: Epigenetic events during the process of cell transformation induced by carcinogens (Review). Oncol Rep. 6:925–932. 1999.PubMed/NCBI
36	Lee KW, Kang NJ, Rogozin EA, et al: Myricetin is a novel natural inhibitor of neoplastic cell transformation and MEK1. Carcinogenesis. 28:1918–1927. 2007. View Article : Google Scholar : PubMed/NCBI
37	Ciardiello F and Tortora G: EGFR antagonists in cancer treatment. N Engl J Med. 358:1160–1174. 2008. View Article : Google Scholar : PubMed/NCBI
38	Gschwind A, Zwick E, Prenzel N, Leserer M and Ullrich A: Cell communication networks: epidermal growth factor receptor transactivation as the paradigm for interreceptor signal transmission. Oncogene. 20:1594–1600. 2001. View Article : Google Scholar
39	Fichera A, Little N, Jagadeeswaran S, et al: Epidermal growth factor receptor signaling is required for microadenoma formation in the mouse azoxymethane model of colonic carcinogenesis. Cancer Res. 67:827–835. 2007. View Article : Google Scholar
40	Wakeling AE, Guy SP, Woodburn JR, et al: ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62:5749–5754. 2002.PubMed/NCBI